Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial

MT Newswires Live

2025/12/16

Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.

It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.

The firm's shares fell 1% in recent trading on Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2591967586"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591967586\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591967586?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 08:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591967586","market":"sg","top_or_hot":-1,"title":"Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.</p><p>It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.</p><p>The firm's shares fell 1% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-16 08:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.</p><p>It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.</p><p>The firm's shares fell 1% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591967586","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591967586","pubTimestamp":1765846096,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.The firm's shares fell 1% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","IMM.AU":"IMMUTEP LTD","BK7067":"生物科技"},"translate_title":"Immutep称近300名患者参加了肺癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.The firm's shares fell 1% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}